Safety Evaluation of Bilateral Same-day Intravitreal Ranibizumab Injections

Purpose: This study aimed to evaluate the safety of bilateral same-day intravitreal ranibizumab injections by analyzing ophthalmic complications. Methods: Medical records of patients who underwent bilateral same-day intravitreal ranibizumab injections between January 2016 and December 2018 were retrospectively reviewed. Patient follow-up visits occurred 1 day, 1 month, and 2 months after the injections. Results: The study included a total of 31 patients, 62 eyes, and 148 bilateral same-day intravitreal ranibizumab injections. The most frequent cause for treatment was exudative age-related macular degeneration, totaling 126 injections (85.1%). Diabetic macular edema accounted for 20 injections (13.5%), and macular edema due to retinal vein occlusion accounted for two injections (1.4%). There were no cases of endophthalmitis, retinal detachment, or vitreous hemorrhage in any patient. We observed five eyes (3.38%) with sterile inflammation, of which three improved without any treatment. The remaining two eyes were in a single patient, and the inflammation improved after four days of treatment. Four eyes (2.7%) exhibited vitreous floaters, and subconjunctival hemorrhage was observed in five eyes (3.38%). Conclusions: The ocular complication rate of bilateral same-day intravitreal ranibizumab injection procedure was low.